Latest From Metacrine Inc.
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.
Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- North America
- Company Type
- Parent & Subsidiaries
- Metacrine Inc.
- Senior Management
Ken Song, Pres. & CEO
Trisha Millican, CFO
Eric Bischoff, SVP, Dev. & Ops.
- Contact Info
Phone: (858) 369-7800
3985 Sorrento Valley Blvd., Ste. C
San Diego, CA 92121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.